These irAEs commonly affect the gastrointestinal tract, with those receiving combination anti–CTLA-4 and PD-1 therapy displaying increased rates of ICI-colitis (32%–37%) compared to those treated with anti–PD-1 monotherapy (4%–6%).1 This evidence concerns the gene PDCD1 and colitis.